The dose, efficacy, and side effects of continuous intravenous infusion (CIVI) of morphine
were compared with continuous subcutaneous infusion (CSCI) of morphine in patients with …

In a prospective and intraindividually controlled trial, we have compared the efficacy and
safety of a continuous subcutaneous morphine infusion with conventional intermittent oral or …

Background: In a multicenter study, 28 patients with cancer pain and insufficient pain relief
with analgesic treatment according to step II of the guidelines of the World Health …

PURPOSE A significant number of cancer patients will require an alternate route of
morphine administration at some point during their illness. This study compared the clinical …

Kadian™/Kapanol™(K) is a capsule formulation of morphine designed for 12-or 24-hourly
dosing. This double-blind study compared the efficacy and safety of K every 24 hr to K every …

Nineteen cancer patients with chronic pain of moderate to severe intensity were randomized
in a double-blind manner to 5 days of either 8-hourly or 12-hourly administration of …

The analgesia and toxicity of regular four-hourly subcutaneous bolus morphine were
assessed prospectively in 164 patients with pain from advanced cancer; each had received …

Background: Patients with cancer pain with initially adequate analgesia under oral
sustained-release opioid medication may suffer from persisting pain exacerbations …

An open-label pilot study was conducted to assess the efficacy and acceptability of a
controlled-release oral morphine formulation, MS Contin tablets, when administered “by the …

The efficacy, safety, and pharmacokinetics of a novel once-daily morphine formulation (OAD
morphine) and a 12-hourly formulation (twice-daily CR morphine) were compared in a …